Longitudinal data of multimorbidity and polypharmacy in older adults in Taiwan from 2000 to 2013

Shih-Wei Lai  
*China Medical University Hospital*, wei@mail.cmuoh.org.tw

Kuan-Fu Liao  
*Taichung Tzu Chi General Hospital*, kuanfuliaog@gmail.com

Cheng-Li Lin  
*Data, China Medical University Hospital, Taichung, Taiwan*, orangechengli@gmail.com

Cheng-Chieh Lin  
*China Medical University Hospital*, cclin@mail.cmuoh.org.tw

Chih-Hsueh Lin  
*China Medical University, Taiwan*, d5496lin@mail.cmu.edu.tw

Follow this and additional works at: https://www.biomedicinej.com/biomedicine

Part of the [Life Sciences Commons](https://www.biomedicinej.com/biomedicine) and the [Medical Sciences Commons](https://www.biomedicinej.com/biomedicine)

This work is licensed under a [Creative Commons Attribution 4.0 License](https://www.biomedicinej.com/biomedicine).

**Recommended Citation**  
Lai, Shih-Wei; Liao, Kuan-Fu; Lin, Cheng-Li; Lin, Cheng-Chieh; and Lin, Chih-Hsueh (2020) "Longitudinal data of multimorbidity and polypharmacy in older adults in Taiwan from 2000 to 2013," *BioMedicine*: Vol. 10 : Iss. 2 , Article 1.  
DOI: 10.37796/2211-8039.1013

This Short Communications is brought to you for free and open access by BioMedicine. It has been accepted for inclusion in BioMedicine by an authorized editor of BioMedicine.
Longitudinal data of multimorbidity and polypharmacy in older adults in Taiwan from 2000 to 2013

Cover Page Footnote
This study was supported in part by the Ministry of Health and Welfare in Taiwan (MOHW109-TDU-B-212-114004), China Medical University Hospital in Taiwan (DMR-107-192 and DMR-108-089), and MOST Clinical Trial Consortium for Stroke (MOST 108-2321-B-039-003), Tseng-Lien Lin Foundation, Taichung, Taiwan. These funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

This short communications is available in BioMedicine: https://www.biomedicinej.com/biomedicine/vol10/iss2/1
Longitudinal data of multimorbidity and polypharmacy in older adults in Taiwan from 2000 to 2013

Shih-Wei Lai¹,², Kuan-Fu Liao³,⁴, Cheng-Li Lin⁵, Cheng-Chieh Lin¹,², Chih-Hsueh Lin¹,²,*  

¹ College of Medicine, China Medical University, Taichung, Taiwan  
² Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan  
³ College of Medicine, Tzu Chi University, Hualien, Taiwan  
⁴ Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan  
⁵ Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan  

Abstract  

Objective: The objective of the study was to evaluate the prevalences and trends of multimorbidity and polypharmacy in older adults in Taiwan. 

Methods: An observational study was performed using the 2000-2013 database of the Taiwan National Health Insurance Program (analysis in 2018). Participants ≥65 years were included in the study. Multimorbidity was defined as participants having two or more chronic diseases annually. Polypharmacy was defined as the average daily number of prescribed medications ≥5. 

Results: The prevalences of multimorbidity were 42.4% in 2000 and 56% in 2013. The prevalences of polypharmacy were 22.9% in 2000 and 32.1% in 2013. 

Conclusions: From 2000 to 2013, multimorbidity and polypharmacy were prevalent among older adults in Taiwan. Public health efforts to intervene the primary prevention for chronic diseases should be considered in older adults. 

Keywords: multimorbidity, older adults, polypharmacy

1. Introduction  

Multimorbidity and polypharmacy in older adults are major public concerns worldwide. Previous studies only focused on the prevalences of multimorbidity and polypharmacy of the year studied. For example, Kirchberger et al reported that the prevalence of multimorbidity (≥2 diseases) was 58.6% in a cross-sectional study of 4127 persons aged 65–94 years in 2012.[1] Junius-Walker et al reported that the prevalence of polypharmacy (≥5 prescribed medications) was 26.7% in a cross-sectional study of 466 older adults in 2007.[2] Moreover, only longitudinal data can well illustrate the long-term trends of multimorbidity and polypharmacy in older adults. Similarly, the increasing number of aging population is also a global challenge. We make a rational hypothesis that there could be an interaction between aging population, multimorbidity, and polypharmacy in older adults. To evaluate this issue, we conducted an observational study to examine the 2000-2013 database of the Taiwan National Health Insurance Program.
2. Methods

2.1. Study design and data source

A population-based observational study was conducted to analyze the 2000-2013 database of the Taiwan National Health Insurance Program. The program was launched in March 1995 and has covered 99.7% of 23 million persons living in Taiwan. The number of people ≥ 65 years can be found in the Ministry of the Interior in Taiwan.

2.2. Sampled participants

Participants ≥ 65 years were included in the study. Multimorbidity was defined as participants having two or more chronic diseases annually. Chronic diseases included 98 diseases approved by the Ministry of Health and Welfare in Taiwan.

2.3. Statistical analysis

We analyzed the number of chronic diseases (0, 1, 2-4, 5-9, and ≥10 diseases) and the number of prescribed medications (0, 1-4, 5-9, and ≥10 medications) per year from 2000 to 2013. The percentages were reported using these data. The aging population, multimorbidity, and polypharmacy were measured annually between 2000 and 2013 and examined with simple correlation regression. All analyses were performed using the SAS statistical software (version 9.2; SAS Institute, Inc., Cary, NC, USA).

Fig. 1. The study flowchart.

Longitudinal health insurance database population (N=1000000)

We identified individuals aged 65 years and older.
Individuals with missing information for age or sex were excluded.

We assessed yearly multimorbidity and polypharmacy among the study participants between 2000 and 2013.
3. Results

In Table 1, the prevalences of multimorbidity were 42.4% in 2000 and 56% in 2013. The prevalences of polypharmacy were 22.9% in 2000 and 32.1% in 2013. The prevalences of adults ≥65 years were 8.6% in 2000 and 11.5% in 2013 (P for trend <0.001).

Fig. 2 disclosed that the prevalences of adults ≥65 years, multimorbidity, and polypharmacy increased at a substantial rate from 2000 to 2013. There seemed to be a parallel increase in the prevalences of aging population, multimorbidity, and polypharmacy in older adults from 2000 to 2013 (P for trend <0.001).

4. Discussion

In this population-based observational study, the prevalences of aging population, multimorbidity, and polypharmacy increased at a substantial rate from 2000 to 2013. There seemed to be a relationship of parallel increase between these three conditions. That is, older adults are at risk for multimorbidity and polypharmacy. Although older adults who have chronic diseases can get benefits from the effective medications but these medications also place those older adults at risk of getting harms. Polypharmacy in older adults is associated with an increased risk of falls, adverse drug reactions, potentially inappropriate medications, frailty, and others.[12-19] An observational using the same Taiwan database disclosed that the prevalence of use of 5 to 9 prescribed drugs daily was 26.3% and the prevalence of use of ≥10 prescribed drugs daily was 5.8% in older people in 2013.[20] An observational study in South Korea disclosed that the prevalence of polypharmacy (≥6 drugs) was 86.4% and the prevalence of major polypharmacy (≥11 drugs) was 44.9% in older people from 2010 and 2011.[21] Moreover, a cross-sectional study in Belgium disclosed that use of 5 to 9 drugs or ≥10 drugs was associated with an increased risk of potentially inappropriate medications (relative risk 2.27 and 4.04, respectively).[16] These results suggest that older adults in Taiwan who had polypharmacy might be potentially at risk of potentially inappropriate medications. In addition, one cohort study in Netherlands disclosed that multimorbidity or polypharmacy at baseline was associated with increased risk of mortality in people with intellectual disability (hazard ratio = 2.61, 95% CI = 1.86-3.66; hazard ratio = 2.32, 95% CI = 1.70-3.16, respectively).[22] Hence, how to break such a relationship between aging population, multimorbidity, and polypharmacy is a public health problem.

The worldwide burden of aging population is increasing annually and currently there is no slowing trend. Polypharmacy is ubiquitous in older adults, and even though an abundance of intervention strategies, it remains uncontrolled. If older adults do not get sick, there might be a chance to break such a relationship between aging population, multimorbidity, and polypharmacy. From the point of preventive medicine, only primary prevention can make sense. Strategies for health promotion and specific protection should be intervened to keep older adults from getting chronic diseases. If chronic diseases can be prevented, the number of medications for treating chronic diseases can be reduced and then polypharmacy can be further reduced. Therefore, the relationship between aging population, multimorbidity, and polypharmacy can be broken.

Some limitations should be discussed. First, numerical definitions of polypharmacy do not always account for specific comorbidities present and make it difficult to assess safety and appropriateness of medications in the clinical setting. How to make a practical definition on polypharmacy is a future research direction. Second, Due to the limitation of

|                        | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | P for trend |
|------------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|-------------|
| Age ≥ 65               | 8.6  | 8.8  | 9.0  | 9.2  | 9.5  | 9.7  | 10   | 10.2 | 10.4 | 10.6 | 10.7 | 10.9 | 11.2 | 11.5 | <0.001      |
| Number of chronic diseases ≥ 2 | 42.4 | 43.8 | 45.4 | 46.6 | 50   | 50.7 | 52.1 | 53.7 | 52.7 | 51.9 | 53.4 | 54.4 | 55.6 | 56  | <0.001      |
| Number of Medications ≥ 5 | 22.9 | 25.3 | 25.7 | 25.8 | 27.6 | 26.8 | 28   | 28.9 | 29.3 | 29.6 | 30.6 | 31.8 | 32.1 |     | <0.001      |
the database used, the impact of “doctor shopping” on polypharmacy cannot be assessed. It indicates a future research direction.

We conclude that from 2000 to 2013, the prevalences of aging population, multimorbidity, and polypharmacy substantially increased in older adults in Taiwan. Public health efforts to intervene the primary prevention for chronic diseases should be considered in older adults.

Authorship statement

Shih-Wei Lai and Kuan-Fu Liao initiated the draft of the article and contributed equally to the article. Cheng-Li Lin, Cheng-Chieh Lin, and Chih-Hsueh Lin conducted data analysis.

Ethical statement

The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Research Ethics Committee of China Medical University and Hospital in Taiwan (CMUH-104-REC2-115). Informed written consent was waived because the study was a retrospective data.

Acknowledgements

This study was supported in part by the Ministry of Health and Welfare in Taiwan, (MOHW109-TDU-B-212-114004), China Medical University Hospital in Taiwan (DMR-107-192 and DMR-108-089), and MOST Clinical Trial Consortium for Stroke (MOST 108-2321-B-039-003). These funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

[1] Kircherberger I, Meisinger C, Heier M, Zimmermann AK, Thorand B, Autenrieth CS, et al. Patterns of multimorbidity in the aged population. Results from the KORA-Age study. PLoS One 2012;7:e30556.
[2] Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy among older primary care patients in Germany. Fam Pract 2007;24:14–9.
[3] Ministry of Health and Welfare Taiwan. Taiwan Health and Welfare Report. http://www.mohw.gov.tw/; 2018 [cited on October 1, 2019, English version].
[4] Liao KF, Lin CL, Lai SW. Association between colorectal cancer and thiazolidinediones administration in a case-control study. Biomedicine (Taipei) 2019;9:31–6.
[5] Household registration statistics data analysis. Department of Household Registration, Ministry of the Interior, Taiwan. https://www.moi.gov.tw [cited in December 1, 2018, English version].
[6] Salive ME. Multimorbidity in Older Adults. Epidemiologic Reviews 2013;35:75–83.
[7] Ministry of Health and Welfare Taiwan. Chronic disease range for national health insurance. http://www.mohw.gov.tw [cited on December 1, 2018, English version].
[8] Gomes MS, Amorim WW, Morais RS, Gama RS, Graia LT, Queiroga HM, et al. Polypharmacy in older patients at primary care units in Brazil. Int J Clin Pharm 2019;41:516–24.
[9] Masnoon N, Shakib S, Kalisch-Ellert L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017;17:230.
[10] Gnijdic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012;65:989–95.
[11] George C, Vergheese J. Polypharmacy and Gait Performance in Community-dwelling Older Adults. J Am Geriatr Soc 2017;65:2082–7.
[12] Chang CB, Chen JH, Wen CJ, Kao HK, Lu IS, Chiu LS, et al. Potentially inappropriate medications in geriatric outpatients with polypharmacy: application of six sets of published explicit criteria. Br J Clin Pharmacol 2011;72:882–9.
[13] Pan HH, Li CY, Chen TJ, Su TP, Wang KY. Association of polypharmacy with fall-related fractures in older Taiwanese people: age- and gender-specific analyses. BMJ Open 2014;4: e004428.
[14] Ahmed B, Nanji K, Mujeeb R, Patel MJ. Effects of polypharmacy on adverse drug reactions among geriatric outpatients at a tertiary care hospital in Karachi: a prospective cohort study. PLoS One 2014;9:e12133.
[15] Saum KU, Schottker B, Meid AD, Holleczek B, Haefeli WE, Hauer K, et al. Is Polypharmacy Associated with Frailty in Older People? Results From the ESTHER Cohort Study. J Am Geriatr Soc 2017;65:e27–32.
[16] Anrys PMS, Strauven GC, Foulon V, Degryse JM, Henrard S, Spinewine A. Potentially Inappropriate Prescribing in Belgian Nursing Homes: Prevalence and Associated Factors. J Am Med Dir Assoc 2014;15:884–90.
[17] Chang CB, Lai HY, Hwang SJ, Yang SY, Wu RS, Liu HC, et al. The application of updating PIM-Taiwan criteria in clinic-visitng older patients with polypharmacy. Ther Adv Drug Saf 2018;9:699–709.
[18] Morin L, Calderon Larranaga A, Welmer AK, Rizzuto D, Wastesson JW, Johnell K. Polypharmacy and injurious falls in older adults: a nationwide nested case-control study. Clin Epidemiol 2019;11:483–93.
[19] Veronese N, Stubbs B, Noale M, Solmi M, Pilotto A, Vaona A, et al. Polypharmacy Is Associated With Higher Frailty Risk in Older People: An 8-Year Longitudinal Cohort Studv. J Am Med Dir Assoc 2017;18:624–8.
[20] Lai SW, Lin CL, Lin CH. Long-Term Trend of Polypharmacy in Older People in Taiwan From 2000 to 2013. J Am Geriatr Soc 2019;67:408–9.
[21] Kim HA, Shin JY, Kim MH, Park BJ. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One 2014;9:e80434.
[22] Schoufour JD, Oppeval A, van der Maarl HJK, Hermans H, Evenhuis HM, Hilgenkamp TIM, et al. Multimorbidity and Polypharmacy Are Independently Associated With Mortality in Older People With Intellectual Disabilities: A 5-Year Follow-Up From the HA-ID Study. Am J Intellect Dev Disabil 2018;123:72–82.